Professor Peter Soyer

Personalised Early Detection of Melanoma

The incidence of melanoma in Australia continues to increase, with Queensland having the highest incidence worldwide. This research uses latest advances in genomics, imaging technologies and microbiopsy devices to develop a personalized screening program for high-risk individuals, with the aim of improving early detection, and reducing the burden of melanoma.

Funded 2018: $585,269

Program: Next Generation Clinical Researchers

Professor David Paterson

Cluster randomised trial of a multimodal intervention to reduce antimicrobial use in residential aged care facilities

Antibiotic resistance in residential aged care facilities is a significant problem. We will be performing a trial in Brisbane facilities in which we use a ten component intervention to reduce antibiotic use. We will study why the bacteria from residential aged care facilities are antibiotic resistant and how they spread from hospitals

Funded 2018: $1,199,976

Program: Tackling Antimicrobial Resistance

Professor Maher Gandhi

An Open label, Multicentre, Phase I study of Ibrutinib, Rituximab and EBV specific T-cells in Patients with EBV-positive Primary or Secondary CNS Lymphoma unsuitable for standard therapies.

Although brain lymphomas are devastating, a number of innovative therapies are in clinical trials to try and improve outcomes. Unfortunately these trials exclude a rare subset of virus driven brain lymphomas that occur in the immunosuppressed for which no therapy exists. Based on our research, we propose an innovative triple therapy regimen that targets the unique biology of viral driven brain lymphomas which we believe will be effective and well-tolerated.

Funded 2018: $1,642,389

Program: Lifting Clinical Trials and Registries Capacity

Professor Claire Wainwright

A platform clinical trial approach to the management of Mycobacterium abscessus complex (MABSC)

Mycobacterium abscessus complex are multi-drug resistant organisms that are now seen more frequently and can result in severe lung infection in vulnerable individuals. There is no current evidence base on which to determine management. Treatment regimens that are currently used are complex, expensive and are often very poorly tolerated and outcomes are variable. This application seeks to set up a platform trial that will provide evidence on which to base management in theĀ  future.

Funded 2018: $2,091,178

Program: Lifting Clinical Trials and Registries Capacity

Professor Janet Hardy

Medicinal Cannabinoids to Relieve Symptom Burden in the Palliative Care of Patients with Advanced Cancer

Medicinal cannabis has proven helpful for symptom relief in a few chronic diseases, but there is limited evidence regarding the benefits and safety for patients with advanced cancer. We will conduct the first clinical trial to rigorously evaluate the efficacy, safety and acceptability of medicinal cannabinoids for symptom relief in advanced cancer patients. The study will define the role of medicinal cannabis in the care of patients with cancer undergoing palliative care.

Funded 2018: $1,363,040

Program: Lifting Clinical Trials and Registries Capacity